Targovax ASA (GB:0RIS) has released an update.
Circio Holding ASA, a Norwegian biotech firm, has announced the approval of its rights issue prospectus by Norway’s Financial Supervisory Authority, with the subscription period for the rights issue set to launch post-annual general meeting approval. The company, known for its circular RNA therapeutics and innovative cancer vaccine TG01, is gearing up for a capital increase through this rights issue, which will be tradable on the Oslo Stock Exchange.
For further insights into GB:0RIS stock, check out TipRanks’ Stock Analysis page.
